Tuesday, February 28, 2012
BioSante Pharmaceuticals Inc., of Lincolnshire, Ill., said results from a 30-patient Phase Ib study demonstrated that its GVAX pancreas cancer vaccine increased the median survival of pancreatic cancer patients with previously treated, locally advanced or metastatic pancreatic adenocarcinoma by more than 60 percent, from 3.3 months when treated with Yervoy (ipilimumab, Bristol-Myers Squibb Co.) to 5.5 months on ipilimumab plus the GVAX pancreas vaccine.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.